Sign in
CompletedPhase 1

A Single Ascending Dose and Multiple Ascending Dose Trial to Assess the Dose, the Efficacy and Oro-sensitivity of Two Modified Linoleic Acids NKS-3 and NKS-5

Key facts

Who runs it
EktaH
Where
Tunisia1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 1
People taking part
120 people enrolled
Started
10 Dec 2025
Ended
26 Oct 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • NKS-3
  • NKS-5
Record updated
9 November 2026

Who can take part

Age
18 years to 60 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 20 criteriaShow less

Who can take part

  • Age between 18 and 60 years (limits included),
  • BMI between 30 and 45 kg/m² (limits included) for obese and BMI between 18.5 and 25 kg/m² (limits included) for healthy volunteers
  • Non smoking (no cigarettes, nor electronic cigarettes),
  • Weight stable within ± 5% in the last month,
  • Good general and mental health with in the opinion of the investigator: no clinically significant and relevant abnormalities of medical history, physical examination or blood sample results at initial visit,
  • Able and willing to participate to the study by complying with the protocol procedures as evidenced by his dated and signed informed consent form,
  • Agree to be registered on the volunteers in biomedical research file

Who cannot take part

  • With significant change in food habits or in physical activity in the 3 months before the initial visit or not agreeing to keep them unchanged throughout the study (no start or stop of physical activity in the next 2 months),
  • With a current or planned in the next 2 months specific diet (hyper or hypocaloric, vegan, vegetarian) or stopped less than 3 months before the initial visit,
  • Taking part in another clinical trial or being in the exclusion period of a previous clinical trial (3 months),
  • Suffering from a metabolic disorder such as diabetes, uncontrolled thyroidal trouble or other metabolic disorder,
  • Suffering from a severe chronic disease (e.g. cancer, HIV, renal failure, hepatic or biliary disorders ongoing, chronic inflammatory digestive disease, arthritis or other chronic respiratory trouble, etc.) or gastrointestinal disorders found to be inconsistent with the conduct of the study by the investigator,
  • With a known or suspected food allergy or intolerance or hypersensitivity to any of the study products' ingredient,
  • Having lost his sense of taste and not fully regaining it following an infection with SARS-CoV-2
  • With a personal history of anorexia nervosa, bulimia or significant eating disorders according to the investigator,
  • Under treatment or dietary supplement which could significantly affect parameters followed during the study according to the investigator or stopped in a too short period before the initial visit,
  • Consuming more than 2 standard drinks of alcoholic beverage daily or not agreeing to keep his alcohol consumption habits unchanged throughout the study,
  • Under legal protection (guardianship, wardship) or deprived from his rights following administrative or judicial decision,
  • Presenting a psychological or linguistic incapability to sign the informed consent,
  • Impossible to contact in case of emergency

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study is designed as a single ascending dose and multiple ascending dose single-blind, placebo controlled, randomized, monocentric trial. 60 obese men and women will be recruited for single ascending dose (Groups 1,2,3), according to the following inclusion and non-inclusion criteria.

Read full original descriptionShow less

60 obese men and women will be recruited for multiple ascending doses (Groups 4,5,6), according to the following inclusion and non-inclusion criteria.

The 2 groups in the trial

  • Obese adults and healthy patients to be administered the treatment NKS-3Existing treatment, for comparison

    Treatment: NKS-3

  • Obese adults and healthy patients to be administered the treatment NKS-5Existing treatment, for comparison

    Treatment: NKS-5

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Single Ascending Dose and Multiple Ascending Dose Single-blind, Placebo-controlled, Randomized, Monocentric Trial to Assess the Dose, the Efficacy and Oro-sensitivity of Two Modified Linoleic Acids NKS-3 and NKS-5
Record updated
9 November 2026